Neuroceuticals iVNS

Bunkyo, Tokyo, JapanFounded 202211–50 employeesncivns.jp

Neuromodulation

Neuroceuticals iVNS is a medical device venture developing neuromodulation technologies. Its lead effort is a catheter-based system that uses vagus nerve stimulation to protect the heart, with an initial focus on heart failure treatment.

Visit ncivns.jp ↗

Founded: 2022
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Neuroceuticals iVNS is a Tokyo-based medical-device company focused on neuromodulation, with its lead effort targeting heart failure treatment. The company was founded on Jun 1, 2022, while the development roots of its technology trace to research at Kyushu University beginning in 2015. Its central product concept is the JOHAKU Vagus Nerve Stimulation Catheter System, designed to stimulate the vagus nerve through the superior vena cava and modulate autonomic nervous system activity. A companion console is described as controlling and delivering stimulation signals. The company also lists external nerve stimulation and cardiac-surgery neuromodulation devices as under development. Its stated approach focuses on cardiac applications, including myocardial protection, rather than general-purpose consumer stimulation. The company’s research direction includes collaboration with cardiovascular researchers and medical advisers, including experts affiliated with the National Cerebral and Cardiovascular Center Research Institute. These details indicate a defined technical focus, but do not establish regulatory clearance, commercial availability, clinical outcomes, or the scale of deployment.

Market position

Neuroceuticals iVNS operates in medical devices and neuromodulation, with a distinctive stated focus on catheter-delivered vagus nerve stimulation for cardiac applications. Its lead system is described as delivering electrical stimulation through a catheter via the superior vena cava, aiming to modulate autonomic activity in the context of heart failure and myocardial protection. That approach differs in form factor and target application from external nerve-stimulation devices, which the company lists separately as under development. The available company profile does not identify verifiable named competitors or provide comparative clinical, regulatory, pricing, or market-share data; naming specific rivals would therefore risk overstating the evidence. Its market position is best characterized as a specialized, development-stage medical-device effort rather than an established commercial platform. Its potential differentiation rests on the catheter-based delivery route and cardiac treatment focus. Demonstrating clinical efficacy, safety, regulatory progress, and adoption would be important to assessing its competitive standing against other neuromodulation approaches.

Growth & opportunities

The company’s development history has two identifiable milestones: the technology’s research roots reportedly began at Kyushu University in 2015, and Neuroceuticals iVNS was founded on Jun 1, 2022. Its product portfolio points to a staged technical agenda centered on the JOHAKU Vagus Nerve Stimulation Catheter System and its companion stimulation console. The company also identifies an external nerve-stimulation device and a cardiac-surgery neuromodulation device as under development, suggesting exploration beyond its catheter-based lead concept. The evidence therefore supports a focused development trajectory, but not a conclusion about acceleration, commercialization, or financial momentum. The clearest potential inflection points to monitor are progression of the JOHAKU system through clinical and regulatory stages and any transition of the additional devices from development into validated products.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Neuroceuticals iVNS distinct

reccy insights

What makes Neuroceuticals iVNS distinct

01Focuses on a medical-device approach to heart failure treatment through vagus nerve stimulation.
02Develops a catheter system intended to deliver stimulation for myocardial protection.
03Technology development traces to Kyushu University research beginning in 2015.
04Works with cardiovascular researchers and medical advisers, including experts affiliated with the National Cerebral and Cardiovascular Center Research Institute.

Technology & products4

Technology & products

JOHAKU Vagus Nerve Stimulation Catheter System
A catheter-based device designed to electrically stimulate the vagus nerve via the superior vena cava to modulate autonomic nervous system activity for heart failure treatment.
Vagus Nerve Stimulation Console
An electronic device that controls and delivers electrical stimulation signals to the vagus nerve via the catheter system.
External Nerve Stimulation Device (under development)
A device intended for non-invasive or external electrical stimulation of nerves, currently in development stages.
Cardiac Surgery Neuromodulation Device (under development)
A device being developed to provide nerve stimulation during cardiac surgery procedures.

Show all 4 products

+ 1 more: Cardiac Surgery Neuromodulation Device (under development)

Similar companies

Show all 6 companies

About Neuroceuticals iVNS

Products: JOHAKU Vagus Nerve Stimulation Catheter System, Vagus Nerve Stimulation Console, External Nerve Stimulation Device (under development), Cardiac Surgery Neuromodulation Device (under development)
Focus areas: NeuroTechnology, medical devices, therapeutics, hardware, neuromodulation, cardiology, heart failure
Headquarters: Bunkyo, Tokyo, Japan
Founded: 2022
Employees: 11–50
Patents granted: 1 (Crunchbase)
Trademarks: 1